This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Abiomed Announces Revenue Of $38.3 Million, Up 19% And Record Impella Patient Usage, Up 26%

The Company is maintaining its fiscal year 2013 revenue guidance in a range of $155 million to $157 million, representing annual growth of 23% to 24%, with worldwide Impella revenues forecast to grow greater than 30%.

The Company will host a conference call to discuss the third quarter fiscal year 2013 results on Wednesday, February 6, 2013, at 8:00 a.m. ET with Michael R. Minogue, Chairman, President and Chief Executive Officer; Robert L. Bowen, Vice President and Chief Financial Officer; and Susan V. Lisa, Senior Director of Investor Relations and Corporate Development.

To listen to the call live, please tune into the webcast via or dial (877) 638-9567; the international number is (253) 237-1032. A replay of this conference call will be available beginning at 11 a.m. ET February 6, 2013 through 11:59 p.m. ET on February 13, 2013. The replay phone number is (855) 859-2056; the international number is (404) 537-3406. The replay access code is 90622458.


Based in Danvers, Massachusetts, Abiomed, Inc., is a leading provider of medical devices that provide circulatory support. Our products are designed to enable the heart to rest by improving blood flow and/or performing the pumping of the heart. For additional information please visit:

The Abiomed logo is available at


This release contains forward-looking statements, including statements regarding development of Abiomed's existing and new products, the Company's progress toward commercial growth, and future opportunities and expected regulatory approvals. The Company's actual results may differ materially from those anticipated in these forward-looking statements based upon a number of factors, including uncertainties associated with development, testing and related regulatory approvals, including the potential for future losses, complex manufacturing, high quality requirements, dependence on limited sources of supply, competition, technological change, government regulation, litigation matters, future capital needs and uncertainty of additional financing, and other risks and challenges detailed in the Company's filings with the Securities and Exchange Commission, including the most recently filed Annual Report on Form 10-K and quarterly report on Form 10-Q. Readers are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this release or to reflect the occurrence of unanticipated events.

Abiomed, Inc. and Subsidiaries
Consolidated Balance Sheets
(in thousands, except share data)
  December 31, 2012 March 31, 2012
Current assets:    
Cash and cash equivalents  $10,757  $5,990
Short-term marketable securities  74,985  71,233
Accounts receivable, net   19,915  20,458
Inventories   14,988  11,142
Prepaid expenses and other current assets  1,357  1,716
Total current assets  122,002  110,539
Property and equipment, net  6,472  6,378
Intangible assets, net  --   115
Goodwill  36,506  36,846
Other long-term assets  29  33
Total assets  $165,009  $153,911
Current liabilities:    
Accounts payable  $6,306  $6,910
Accrued expenses  13,883  12,480
Deferred revenue  3,100  3,025
Total current liabilities  23,289  22,415
Long-term deferred tax liability  5,344  4,799
Other long-term liabilities  331  400
Total liabilities  28,964  27,614
Commitments and contingencies    
Stockholders' equity:    
Class B Preferred Stock, $.01 par value  --   -- 
Authorized - 1,000,000 shares; Issued and outstanding - none    
Common stock, $.01 par value  397  393
Authorized - 100,000,000 shares;     
Issued - 39,742,737 shares at December 31, 2012 and 39,323,708 shares at March 31, 2012;    
Outstanding - 38,880,393 shares at December 31, 2012 and 39,272,754 shares at March 31, 2012    
Additional paid in capital  411,715  401,771
Accumulated deficit  (262,003)  (273,275)
Treasury stock at cost - 862,344 shares at December 31, 2012 and 50,954 shares at March 31, 2012  (11,719)  (827)
Accumulated other comprehensive loss  (2,345)  (1,765)
Total stockholders' equity  136,045  126,297
Total liabilities and stockholders' equity  $165,009  $153,911
Abiomed, Inc. and Subsidiaries
Consolidated Statements of Operations
(in thousands, except share data)
  Three Months Ended December 31, Nine Months Ended December 31,
  2012 2011 2012 2011
Product revenue  $38,112  $31,732  $114,078  $88,049
Funded research and development  138  466  372  982
   38,250  32,198  114,450  89,031
Costs and expenses:        
Cost of product revenue   8,130  6,279  22,770  17,721
Research and development   6,259  6,140  18,825  19,923
Selling, general and administrative   20,943  17,184  60,333  51,683
Amortization of intangible assets  --   362  111  1,126
   35,332  29,965  102,039  90,453
Income (loss) from operations  2,918  2,233  12,411  (1,422)
Other income:        
Investment income (expense), net  1  (2)  --   (4)
Gain on settlement of investment  --   1,017 --   1,017
Other income, net  324  39  311  24
   325  1,054  311  1,037
Income (loss) before income tax provision  3,243  3,287  12,722  (385)
Income tax provision  559  366  1,450  687
Net income (loss) $2,684  $2,921  $11,272  $(1,072)
Basic net income (loss) per share  $0.07  $0.08 $ 0.29  $(0.03)
Basic weighted average shares outstanding  39,417  38,498  39,331  38,221
Diluted net income (loss) per share  $0.07  $0.07 $0.27  $(0.03)
Diluted weighted average shares outstanding  40,865  40,270  41,418  38,221
CONTACT: Susie Lisa, CFA
         Senior Director, Investor Relations and Corporate Development
         Aimee Maillett
         Corporate Communications Manager

Abiomed Logo

2 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,712.66 +34.43 0.19%
S&P 500 2,061.02 +4.87 0.24%
NASDAQ 4,891.2190 +27.8570 0.57%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs